is there still a glp-1 shortage Drug Shortages How WellSync Overcomes the GLP-1
Description
Research peptide access provides a bridge for those unwilling to wait two to three additional years for pharmaceutical availability
10.1002/cmdc.201200409 174
By combining the actions of both GLP-1 and GIP, Tirzepatide enhances insulin secretion and reduces glucagon release
Bydureons clinical positioning : It offered convenience of weekly dosing and better morning fasting glucose control than Byetta (since drug is always present)
placebo, genital mycotic infections were seen in greater than 10% of women (100mg-10.4%, 300 mg-11.4%, placebo-3.2%) and around 4% of men (100 mg-4.2%, 300 mg-3.7%, placebo- 0.6%) (213)
